<DOC>
	<DOCNO>NCT00005580</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase I trial study effectiveness bryostatin 1 plus fludarabine treating patient chronic lymphocytic leukemia relapse , indolent non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Bryostatin + Fludarabine Treating Patients With Chronic Lymphocytic Leukemia Relapsed Indolent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine toxic effect maximum tolerate dose bryostatin 1 fludarabine patient symptomatic advance chronic lymphocytic leukemia relapse indolent non-Hodgkin 's lymphoma . - Monitor apoptosis , differentiation , protein kinase C activity leukemic lymphocyte expose vivo bryostatin 1 fludarabine . - Observe antitumor activity combination therapy patient . OUTLINE : This dose-escalation , multicenter study . Patients assign one two treatment group . - Group I : Patients receive bryostatin 1 IV 24 hour follow fludarabine IV 30 minute daily day 1-5 . - Group II : Patients receive fludarabine IV 30 minute daily day 1-5 follow bryostatin 1 IV 24 hour . In group , course repeat every 4 week patient stable respond disease . Cohorts 3-6 patient receive escalate dos fludarabine bryostatin 1 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD fludarabine determine , dose bryostatin 1 escalate . PROJECTED ACCRUAL : Approximately 30-60 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm chronic lymphocytic leukemia Stage I ( symptomatic bulky lymphadenopathy ) Stage II , III , IV Prior chemotherapy allow , include fludarabine purine nucleoside analog therapy OR Histologically confirm indolent nonHodgkin 's lymphoma Progressive relapse follow chemotherapy Includes follow histology : Bcell chronic lymphocytic leukemia/prolymphocytic leukemia/lymphomas Lymphoplasmacytoid lymphoma ( Waldenstrom 's ) /immunocytoma Mantle cell lymphoma Follicular lymphoma Small cell Mixed small large cell Diffuse ( predominately small cell type ) Marginal zone Bcell lymphoma Extranodal ( MALTtype without monocytoid Bcells ) Provisional subtype : nodal ( without monocytoid Bcells ) Provisional entity : splenic marginal zone lymphoma ( without villous lymphocyte ) Hairy cell leukemia Peripheral Tcell NKcell neoplasms Tcell chronic lymphocytic leukemia/polylymphocytic leukemia Large granular lymphocyte leukemia Tcell type NKcell type Mycosis fungoides/Sezary 's syndrome ( cutaneous Tcell lymphoma ) No CNS disease PATIENT CHARACTERISTICS : Age : 18 Performance status : Zubrod 02 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,000/mm3 Platelet count least 75,000/mm3 Hemoglobin least 8 g/dL Coombs negative Hepatic : AST/ALT great 2.5 time upper limit normal Bilirubin great 2 mg/mL Renal : Creatinine clearance least 40 mL/min Other : No concurrent neurologic condition No concurrent medical condition would preclude study Not pregnant nursing Fertile patient must use effective contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent systemic immunoglobulin therapy No prior bone marrow peripheral stem cell transplantation Chemotherapy : See Disease Characteristics At least 3 week since prior systemic chemotherapy Endocrine therapy : No concurrent systemic glucocorticoid therapy Radiotherapy : Not specify Surgery : Not specify Other : No concurrent anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>T-cell large granular lymphocyte leukemia</keyword>
	<keyword>B-cell chronic lymphocytic leukemia</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>